Clinical Trial Update: A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on safety, efficacy, and pharmacokinetics of mosunetuzumab as a single agent and with atezolizumab in chronic lymphocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin | Phase 1, Phase 2 | Status: COMPLETED